Do Gut Hormones Mediate the Beneficial Effects of Roux-en-Y Bypass?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Imperial College London
- Enrollment
- 190
- Locations
- 1
- Primary Endpoint
- Weight loss
Study Overview
Brief Summary
The purpose of this study is to assess whether the changes in gut hormones seen following Roux en Y Gastric Bypass surgery are responsible for some of the beneficial effects seen post-operatively.
Detailed Description
This study is designed to investigate whether chronic elevation of glucagon-like peptide-1 (GLP-1), oxyntomodulin and peptide YY (PYY) in combination is responsible for the majority of the metabolic effects of Roux-en-Y gastric bypass (RYGB) including improved glycaemia, increased energy expenditure, reduced food intake, weight loss, reduced preference for high calorie foods and reduced activation in brain reward areas in response to visual food cues.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Weight loss
Time Frame: Baseline - 4 weeks
Weight loss as measured at baseline compared to 4 weeks after infusion or diet
Secondary Outcomes
- Glycaemia(Baseline - 4 weeks)